AUTL vs LEN · rev $10.1M vs rev $34.19B
Autolus Therapeutics Ltd (AUTL) versus LEN (LEN) — a side-by-side from cached financials, not a winner call.
Autolus Therapeutics Ltd (AUTL) is a biotechnology company listed on US.
LEN (LEN) common stock.
Latest reported AUTL revenue for 2024-12-31 was $10.1M. Net income was -$220.7M. Revenue was up 496.0% from 2023-12-31 to 2024-12-31. AUTL currently screens at market cap $614.8M.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
AUTL currently screens at market cap $614.8M. LEN currently screens at market cap $0.
Not investment advice. Open the AUTL and LEN stock pages for the full models.
Not investment advice.